Favorable outcome of central nervous system toxoplasmosis occurring in a patient with untreated Hodgkin's disease.
The current report describes severe, multi-focal central nervous system (CNS) toxoplasmosis in a patient with untreated Hodgkin's disease. Anti-toxoplasma therapy was associated with prompt clinical improvement, and as such may represent the first successfully treated case of global CNS-toxoplasmosis occurring in a person with histologically documented lymphoma. Previously, CNS-toxoplasmosis has been noted to complicate lymphomas after initiation of anti-neoplastic therapy. The occurrence of disseminated toxoplasmosis prior to anti-neoplastic therapy is unique and suggests that lymphoma per se is a predisposing factor.
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002493:Central Nervous System Diseases / Q000150:complications* / Q000188:drug therapy / Q000209:etiology; D004359:Drug Therapy, Combination; D006689:Hodgkin Disease / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D008297:Male; D011739:Pyrimethamine / Q000008:administration & dosage; D012075:Remission, Spontaneous; D013411:Sulfadiazine / Q000008:administration & dosage; D014123:Toxoplasmosis / Q000150:complications* / Q000188:drug therapy / Q000209:etiology
D000970:Antineoplastic Agents; D013411:Sulfadiazine; D011739:Pyrimethamine